Skip to NavigationSkip to content

Pharmafile - Medical Communications News

-Keytruda's liver cancer failure -A "game-changing osteoasrthritis treatment - AstraZeneca retires the MedImmune brand -Promise of the first new...
The Justice Department and US Securities and Exchanges Commission are investigation healthcare giant Johnson & Johnson over allegations that...
UK drug watchdog The Medicines and Healthcare products Regulatory Agency (MHRA) has warned of the potential side-effects of Neo-mercazole (...
The twins who were genetically modified using the gene editing tool CRISPR may have been changed in a way that could enhance their memory and...
The number of phone calls to US poison control centres over exposures to kratom – an herbal drug with opioid properties and stimulant like effects...
Boehringer Ingelheim and Eli Lilly’s Trajenta (linagliptin) met its primary endpoint in a recent trial, it has emerged, proving itself non-inferior...
- Janssen's esketamine drug recommended by FDA panel for depression - Researchers find new type of cell membrane which causes cancer cells to explode...
NICE has announced its decision to authorise the use of Roche’s Perjeta (pertuzumab) on the NHS for the treatment of HER2-positive breast cancer...
AstraZeneca is retiring the MedImmune brand as part of a restructuring that will see biologics integrated into two new R&D units.
Lundbeck and Otsuka’s treatment for bipolar disorder, Rexulti, failed to achieve its primary endpoint in two separate Phase 3 trials.
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches